Gilmelisib is a potent small-molecule inhibitor targeting the PI3K p110α and PI3Kδ isoforms, currently under investigation as a kinase inhibitor for the treatment of various non-Hodgkin lymphomas, including… Read more
Gilmelisib is a potent small-molecule inhibitor targeting the PI3K p110α and PI3Kδ isoforms, currently under investigation as a kinase inhibitor for the treatment of various non-Hodgkin lymphomas, including mantle cell lymphoma. Laboratories involved in pharmaceutical research and quality control rely on this category of Gilmelisib reference standards to support rigorous analytical testing and method development. By providing access to the active drug alongside its specific impurities and related metabolites, these compounds enable accurate impurity profiling and facilitate the validation of analytical methods during development processes. Utilizing these high-quality reference materials ensures that analytical techniques are capable of identifying and quantifying trace levels of related substances, which is critical for meeting regulatory requirements and maintaining consistency throughout the manufacturing lifecycle of the drug substance.